AIFAM（TBAP Management Company）
- Established in 2001 as an Investment Manager for alternative investments (hedge funds, private equity, venture capital funds) Manages over $700mn with 22 professionals, located in New York and Tokyo.
- Lead investment manager for alternative investments of top-tier Japanese institutional investors providing custom tailored solutions.
TBAP Advisory Board Members
Takashi Kiyoizumi, MD, PhD, SM
Mr. Takashi Kiyoizumi is a life science entrepreneur and executive with over 30 years of experience as well as a board certified plastic surgeon. As a founding President and CEO of MediciNova, he raised over $190 million in private placements and a successful IPO, within 5 years of inception. Prior to founding MediciNova, he was President and CEO of Tanabe Research Laboratories, USA (U.S. affiliate of Mitsubishi Tanabe Pharma). Since 2005, he has been an active angel investor/board member with various life science ventures in San Diego.
- M.D. and Ph.D. from Keio University School of Medicine
- MBA from Sloan School of Management at MIT
Mr. Suzuki started his 40+ yrs career in healthcare/life sciences with Kyowa Hakko. Recently, he held a series of management positions at Japan divisions of global companies, Baxter Japan, Alcon Japan, and Affymetrix Japan (CEO), Bio-Rad Laboratories Japan (CEO),Cepheid Japan,(CEO). Currently, he is the head of the Japan office of Newton Biocapital (Belgium base VC). He has extensive experience working with Japanese regulatory authorities on securing the approval of medical devices, testing equipment, reagents and compounds.
- MBA from Kellogg School at Northwestern Univ.
Fumitaka Mori, Ph.D.
Partner at Taiho Innovations, LLC
Mr. Mori is a senior member of Taiho Innovations, which focuses on seed to early stage investments and company creation, following 5 years of venture investments at Remiges Ventures Boston. Prior to his experience in Venture Capital firm, he has over 12 years of experience in drug discovery research, strategic research planning, research alliances and portfolio strategy at Taiho Pharmaceutical. He received his Ph.D. in Clinical Pharmaceutical Sciences from the University of Shizuoka.
Yoshiharu Mizui, Ph.D.
President of Eisai Innovation, Inc. & Head of Cambridge office
Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai from 2016-2019. He was also a founding member of H3 Biomedicine and lead the oncology program from 2011-2016. He has more than 20 years of experience as a discovery research biologist. He received his Ph.D. from Kyushu University.
Sadakazu Miyashita, MS
Mr. Miyashita is presently Director of Corporate Venture Investment with Eisai Co, Ltd. Prior to this, he held roles in corporate strategy with a focus on business development as well as being stationed in Andover, MA where he was head of Portfolio Management of Andover Innovation Medicines. While at Andover, he assumed executive responsibility for drug discovery research through direct collaborations with peer laboratories involved in early stage pharmaceutical development. Before that, he has 15 years of experience as a biologist in drug discovery research along with management rolls related to strategic planning in Eisai’s laboratories. Mr. Miyashita received his MS in Molecular Biology from Gifu Pharmaceutical University.